The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: A Japanese multicenter randomized, controlled study

International Journal of Hematology

Volumn 85, Issue 2, 2007, Pages 121-127

  Ito, Yoshikazu ^a   Ohyashiki, Kazuma ^a   Yoshida, Isao ^b   Takeuchi, Makoto ^b   Aoyama, Yasutaka ^c   Mugitani, Atsuko ^c   Matsuura, Yasuhiro ^d   Wakita, Hisashi ^d   Matsuda, Mitsuhiro ^e   Sakamoto, Erina ^f   Kiguchi, Toru ^g   Urabe, Akio ^h   Tamura, Kazuo ⁱ   Kanamaru, Akihisa ^e   Masaoka, Toru ^j   Hasegawa, Hirofumi ^k   Hino, Masayuki ^l   Hirai, Manabu ^m   Ueda, Yasunori ⁿ   Shigeno, Kazuyuki ^o   Ohnishi, Kazunori ^o   Iwasaki, Hiromichi ^p   Goto, Tetsuya ^q   Ozaki, Keiji ^q   Iijima, Kimiko ^r   Sakai, Chikara ^s   Miyamura, Koichi ^t   Toubai, Tomomi ^u   Imamura, Masahiro ^u   Nakagawa, Yasunori ^v   Suzuki, Kenshi ^v   Akiyama, Nobu ^w   Shimada, Takaki ^x   Mizorogi, Fumi ^x   Wada, Hideho ^y   Mihara, Hidetsugu ^z   Uoshima, Nobuhiko ^aa   Tashima, Masarou ^ab   Taniwaki, Masafumi ^ac   Miyata, Akira ^ad   Hirokawa, Makoto ^ae   Sawada, Kenichi ^ae   Watanabe, Kentaro ^af   Sugawara, Hiroyuki ^ag   Kanakura, Yuzuru ^ag   Tamaki, Toshiharu ^ah   Misawa, Mahito ^ai   Hara, Hiroshi ^ai   Karasawa, Hiromi ^aj   Agou, Hiroatsu ^ak   more..

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b Department of Internal Medicine   (Japan)

^c Fuchu Hospital   (Japan)

^d NARITA RED CROSS HOSPITAL   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g KAGAWA ROSAI HOSPITAL   (Japan)

^h Kanto Teishin Hospital   (Japan)

ⁱ FUKUOKA UNIVERSITY   (Japan)

^j OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^k KINKI UNIVERSITY   (Japan)

^l Osaka Prefecture University   (Japan)

^m OSAKA CITY GENERAL HOSPITAL   (Japan)

ⁿ KURASHIKI CENTRAL HOSPITAL   (Japan)

^o HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p UNIVERSITY OF FUKUI   (Japan)

^q TOKUSHIMA RED CROSS HOSPITAL   (Japan)

^r NIT Kanto Medical Center

^s CHIBA CANCER CENTER   (Japan)

^t JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^u HOKKAIDO UNIVERSITY   (Japan)

^v JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^w TOKYO METROPOLITAN BOKUTOH HOSPITAL   (Japan)

^x JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^y KAWASAKI MEDICAL SCHOOL   (Japan)

^z AICHI MEDICAL UNIVERSITY   (Japan)

^aa MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^ab TAKATSUKI RED CROSS HOSPITAL   (Japan)

^ac KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^ad CHUGOKU CENTRAL HOSPITAL   (Japan)

^ae AKITA UNIVERSITY   (Japan)

^af SAISEIKAI CENTRAL HOSPITAL   (Japan)

^ag OSAKA UNIVERSITY   (Japan)

^ah Izumisano Municipal Hospital   (Japan)

^ai HYOGO COLLEGE OF MEDICINE   (Japan)

^aj KANAZAWA MEDICAL UNIVERSITY   (Japan)

^ak SHIMANE PREFECTURAL CENTRAL HOSPITAL   (Japan)

more..

Author keywords

Acute myeloid leukemia; Chemotherapy; Fungal infection; Myelodysplastic syndromes; Prophylaxis

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; LEVOFLOXACIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CAPSULE; DRUG EFFICACY; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; GINGIVITIS; GRAM NEGATIVE INFECTION; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC MYCOSIS;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CAPSULES; FEMALE; FLUCONAZOLE; HUMANS; ITRACONAZOLE; JAPAN; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MYCOSES; MYELODYSPLASTIC SYNDROMES;

EID: 33847633134     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06079     Document Type: Article

References (29)

1. Bow EJ, Laverdière M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients. Cancer. 2002;94:3230-3246.
2. Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. British Society for Antimicrobial Chemotherapy Working Party. Cancer. 2000;89:1611-1625.
3. Shivji A, Noble MA, Bernstein M. Laboratory monitoring of antifungal chemotherapy. British Society for Antimicrobial Chemotherapy Working Party. Lancet. 1991;337:1577-1580.
4. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother. 1998;42:741-745.
5. Glasmacher A, Prentice A, Gorschlüter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol. 2003;21:4615-4626.
6. Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol. 2005;131:22-28.
7. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, de Beule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses. 1989;32:103-108.
8. Toubai T, Tanaka J, Fujisawa F, Kondo Y, Imamura M. Effect of prophylaxis against mycosis in patients with hematological malignancy disease: efficacy of dosage of itraconazole [in Japanese]. Jpn J Antibiot. 2003;56:61-65.
9. Tamura K, Imajo K, Akiyama N, et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clin Infect Dis. 2004;39:S15-S24.
10. Yoshida M, Akiyama N, Takahashi M, et al. Management of infectious complications in patients with acute leukemia during chemotherapy: a questionnaire analysis by the Japan Adult Leukemia Study Group [in Japanese]. Jpn J Chemother. 2003;51:703-710.
11. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infection in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845-851.
12. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective randomized doubleblind study. J Infect Dis. 1995;171:1545-1552.
13. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
14. Deep-seated Mycosis Guidelines Editorial Committee. Guidelines for the Diagnosis and the Treatment of Deep-Seated Mycosis [in Japanese]. Tokyo, Japan: Ishiyaku Publishers; 2003.
15. Klastersky J. Febrile neutropenia. Curr Opin Oncol. 1993;5:625-632.
16. Klastersky J. Anti-fungal therapy in patients with fever and neutropenia: more rational and less empirical? N Engl J Med. 2004;351:1445-1447.
17. Annaloro C, Oriana A, Tagliaferri E, et al. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica. 1995;80:512-517.
18. Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW, on behalf of the U.K. Multicentre Antifungal Prophylaxis Study Group. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol. 1999;105:901-911.
19. Hüijgens PG, Simoons-Smit AM, van Loenen AC, et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol. 1999;52:376-380.
20. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term anti-fungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. Ann Intern Med. 2003;138:705-713.
21. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103:1527-1533.
22. Falagas ME, Vardakas KZ, Michalopoulos A. In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancies: response to Prentice et al. Br J Haematol. 2006;132:658-659.
23. Prentice AG, Glasmacher A, Djulbegvic B. In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancies. Br J Haematol. 2006;132:656-658.
24. Yamaguchi N, Ito Y, Ohyashiki K. Increased intracellular activity of matrix metalloproteinases in neutrophils may be associated with delayed healing of infection without neutropenia in myelodysplastic syndromes. Ann Hematol. 2005;84:383-388.
25. Mühlemann K, Wenger C, Zenhäesern R, Täuber MG. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia. 2005;19:545-550.
26. Maschmeyer G, Ruhnke M. Update on antifungal treatment of invasive Candida and Aspergillus infections. Mycoses. 2003;47:263-276.
27. Kamaluddin M, McNally P, Breatnach F, et al. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr. 2001;90:1204-1207.
28. Kageyama S, Masuya M, Tanaka I, et al. Plasma concentration of itraconazole and prophylactic efficacy in patients with neutropenia after chemotherapy for acute leukemia. J Infect Chemother 1999;5:213-216.
29. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother. 2005;56(suppl 1):i17-i22.